May 28, 2019
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
Apr 30, 2019
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Mar 20, 2019
Trizell Ltd. announces Phase 3 pivotal study of interferon alfa-2b gene therapy in malignant pleural mesothelioma
Feb 21, 2019
PharmaEssentia and AOP Orphan Receive EU Approval of Besremi(TM) (Ropeginterferon Alfa-2b) for Treatment of Polycythemia Vera (PV) in EU
Jan 13, 2019
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
Dec 17, 2018
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Dec 17, 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Dec 05, 2018
PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program
Oct 29, 2018
MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta
Oct 17, 2018
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
Oct 08, 2018
New Efficacy and Safety Data on MS Portfolio to Be Presented at ECTRIMS 2018
Sep 24, 2018
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
Aug 15, 2018
PEGylated Drugs Market in Europe and North America will achieve 5% CAGR to bypass $10.5 Billion by 2024
Aug 06, 2018
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
Jun 22, 2018
Scientists Discover How Antiviral Gene Works
May 18, 2018
Growth Factors (Blood and Tissue) - 2018 Global Strategic Business Report Analysis & Forecasts (2016-2024) - Burgeoning Global Population Offers Significant Growth Opportunities
May 11, 2018
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Apr 13, 2018
EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets and Rebif® Data at AAN 2018
Mar 21, 2018
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
Feb 22, 2018
MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B